NEURIZON THERAPEUTICS LIMITED (NUZ)
Share Price Analysis and Chart

18/11/2024

1

Speculative Buy

$0.42

189.66%

Neurizon Therapeutics released data showing NUZ-001 reduces protein aggregation, including TDP-43, which Morgans highlights as a contributor to the development of Amyotrophic Lateral Sclerosis (ALS), commonly known as motor neurone disease.

The results indicated a notable reduction in DNA-tar binding protein 43 in motor neurons by approximately -50% to -55%, a key feature of ALS.

The Speculative Buy rating and 42c target price are retained. The broker believes Neurizon Therapeutics presents a robust proposition in the rare disease segment.

FORECAST
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.00 cents.
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.

19/02/2025

1

Buy

$0.45

210.34%

The US FDA has requested a single piece of additional information from Neurizon Therapeutics to resolve the clinical hold placed on NUZ-001 last month. There were no safety flags, and Petra Capital sees the data request as easily addressable and with minimal cost impact.

While this modestly delays the start of the potentially registrational HEALEY amyotrophic lateral sclerosis (ALS) trial by around six months, Petra sees the path to opening of an investigational new drug (IND), a pre-requisite to start US clinical trials, as materially de-risked.

Target falls to 45c from 47c, Buy retained.

FORECAST
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -3.00 cents.
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -3.20 cents.